{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T14:42:41Z","timestamp":1764945761889,"version":"3.46.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Espa\u00f1ola de Geriatr\u00eda y Gerontolog\u00eda"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.regg.2025.101717","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T07:53:10Z","timestamp":1756367590000},"page":"101717","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluating ferric carboxymaltose administration in elderly patients: Clinical outcomes, comparative characteristics in different care settings and cost analysis. A five year study"],"prefix":"10.1016","volume":"60","author":[{"given":"Mar\u00eda Noem\u00ed","family":"Garc\u00eda-Calder\u00f3n D\u00edaz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Medina Nieto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mateo","family":"Ballesteros Arana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Manzanilla Meneses","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelyn","family":"Barriga Pineda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Garc\u00eda Matta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela","family":"Castro Medina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Tornero Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"G\u00f3mez Pav\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.regg.2025.101717_bib0125","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1002\/ehf2.12797","article-title":"Anaemia, iron deficiency and heart failure in 2020: facts and numbers","volume":"7","author":"Chopra","year":"2020","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.regg.2025.101717_bib0130","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3389\/fphar.2014.00083","article-title":"Iron deficiency in the elderly population, revisited in the hepcidin era","volume":"5","author":"Busti","year":"2014","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.regg.2025.101717_bib0135","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s40265-014-0332-3","article-title":"Ferric carboxymaltose: a review of its use in iron deficiency","volume":"75","author":"Keating","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.regg.2025.101717_bib0140","first-page":"1","article-title":"Treatment of iron deficiency in the elderly: a new paradigm","volume":"2019","author":"Auerbach","year":"2019","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.regg.2025.101717_bib0145","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1080\/14740338.2021.1912010","article-title":"Newer formulations of intravenous iron: a review of their chemistry and key safety aspects\u2014hypersensitivity, hypophosphatemia, and cardiovascular safety","volume":"20","author":"Blumenstein","year":"2021","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.regg.2025.101717_bib0150","first-page":"239","article-title":"Intravenous iron therapy in heart failure","volume":"15","author":"Altman","year":"2018","journal-title":"Curr Heart Fail Rep"},{"volume":"145","journal-title":"Circulation","year":"2022","key":"10.1016\/j.regg.2025.101717_bib0155"},{"key":"10.1016\/j.regg.2025.101717_bib0160","first-page":"390","article-title":"Roles of intravenous iron therapy in various patient settings","volume":"13","author":"Nguyen","year":"2010","journal-title":"J Pharm Pharm Sci"},{"key":"10.1016\/j.regg.2025.101717_bib0165","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.jacc.2006.07.015","article-title":"Intravenous iron alone for the treatment of anemia in patients with chronic heart failure","volume":"48","author":"Bolger","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.regg.2025.101717_bib0170","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1182\/asheducation-2010.1.338","article-title":"Clinical use of intravenous iron: administration, efficacy, and safety","volume":"2010","author":"Auerbach","year":"2010","journal-title":"Hematol Am Soc Hematol Educ Program"},{"journal-title":"AEMPS","article-title":"Preparados de hierro de administraci\u00f3n intravenosa y reacciones de hipersensibilidad: nuevas recomendaciones. Nota Informativa MUH (FV), 12\/2013","year":"2013","key":"10.1016\/j.regg.2025.101717_bib0175"},{"key":"10.1016\/j.regg.2025.101717_bib0180","article-title":"Delayed hypersensitivity reaction to iron salts: from diagnosis to desensitization","volume":"10","author":"Carr\u00f3n-Herrero","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.regg.2025.101717_bib0185","first-page":"522","article-title":"Manejo del d\u00e9ficit de hierro en distintas situaciones cl\u00ednicas y papel del hierro intravenoso: recomendaciones del Grupo Espa\u00f1ol de Eritropatolog\u00eda de la SEHH","volume":"220","author":"Garc\u00eda-Erce","year":"2020","journal-title":"Rev Clin Esp (Barc)"},{"key":"10.1016\/j.regg.2025.101717_bib0190","first-page":"817","article-title":"Initial experiences of an in-reach service providing iron infusions in residential aged care facilities","volume":"44","author":"Zinsaz","year":"2020","journal-title":"Aust Health Rev"},{"key":"10.1016\/j.regg.2025.101717_bib0195","first-page":"450","article-title":"Characterization of the population with severe iron deficiency anemia at risk of requiring intravenous iron supplementation","volume":"43","author":"Estadella","year":"2018","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.regg.2025.101717_bib0200","doi-asserted-by":"crossref","first-page":"123","DOI":"10.4212\/cjhp.v71i3.2583","article-title":"Ferric gluconate complex in elderly hospital inpatients without terminal kidney failure","volume":"71","author":"Nguyen","year":"2018","journal-title":"Can J Hosp Pharm"},{"key":"10.1016\/j.regg.2025.101717_bib0205","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3390\/jcm11185284","article-title":"Efficacy, safety and pharmacoeconomic analysis of intravenous ferric carboxymaltose in anemic hemodialysis patients unresponsive to ferric gluconate treatment: a multicenter retrospective study","volume":"11","author":"Rosati","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.regg.2025.101717_bib0210","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.mayocp.2014.10.007","article-title":"The safety of intravenous iron preparations: systematic review and meta-analysis","volume":"90","author":"Avni","year":"2015","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.regg.2025.101717_bib0215","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1093\/ndt\/gfw264","article-title":"Safety of intravenous ferric carboxymaltose versus oral iron in patients with nondialysis-dependent CKD: an analysis of the 1-year FIND-CKD trial","volume":"32","author":"Roger","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.regg.2025.101717_bib0220","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1007\/s12325-019-01089-z","article-title":"Economic evaluation of ferric carboxymaltose for the management of hemodialysis patients with iron deficiency anemia in Italy","volume":"36","author":"Rognoni","year":"2019","journal-title":"Adv Ther"},{"key":"10.1016\/j.regg.2025.101717_bib0225","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/3106890","article-title":"Efficacy and tolerability of intravenous ferric carboxymaltose in patients with iron deficiency at a hospital outpatient clinic: a retrospective cohort study of real-world clinical practice","volume":"2017","author":"Robalo Nunes","year":"2017","journal-title":"Anemia"},{"key":"10.1016\/j.regg.2025.101717_bib0230","first-page":"1","article-title":"Pharmacodynamics and safety of ferric carboxymaltose: a multiple-dose study in patients with iron-deficiency anaemia secondary to a gastrointestinal disorder","volume":"61","author":"Geisser","year":"2011","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.regg.2025.101717_bib0235","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s10198-013-0533-9","article-title":"Budget impact of parenteral iron treatment of iron deficiency: methodological issues raised by using real-life data","volume":"15","author":"Braunhofer","year":"2014","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.regg.2025.101717_bib0240","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1093\/eurjhf\/hfs083","article-title":"Health economic assessment of ferric carboxymaltose in patients with iron deficiency and chronic heart failure based on the FAIR-HF trial: an analysis for the UK","volume":"14","author":"Gutzwiller","year":"2012","journal-title":"Eur J Heart Fail"}],"container-title":["Revista Espa\u00f1ola de Geriatr\u00eda y Gerontolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0211139X25000976?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0211139X25000976?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T14:40:37Z","timestamp":1764945637000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0211139X25000976"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0211139X25000976"],"URL":"https:\/\/doi.org\/10.1016\/j.regg.2025.101717","relation":{},"ISSN":["0211-139X"],"issn-type":[{"type":"print","value":"0211-139X"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluating ferric carboxymaltose administration in elderly patients: Clinical outcomes, comparative characteristics in different care settings and cost analysis. A five year study","name":"articletitle","label":"Article Title"},{"value":"Revista Espa\u00f1ola de Geriatr\u00eda y Gerontolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.regg.2025.101717","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 SEGG. Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101717"}}